Nature Publication Shows Mission Bio's Tapestri® Platform Enables Real-Time, Single-Cell Tracking of Precancerous Clones Using Natural Epigenetic Markers
Epigenetic barcoding incorporating Tapestri unlocks high-throughput single-cell lineage tracing of clonality with or without mutation drivers, a previously invisible precursor to cancer development
EPI-clone, developed by researchers at Centre for Genomic Regulation and Institute for Research in Biomedicine, tracks clonal dynamics in hematopoiesis with naturally occurring DNA methylation patterns, laying the groundwork for discovering new cancer progression mechanisms and therapeutic targets
SOUTH SAN FRANCISCO, Calif., May 21, 2025--(BUSINESS WIRE)--Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced a new publication in Nature leveraging its Tapestri Platform to develop a single-cell barcoding method for high-throughput cell lineage tracing. Study leader Lars Velten and his team at Spain's Centre for Genomic Regulation (CRG), working with a group led by Alejo Rodriguez-Fraticelli at the Institute for Research in Biomedicine (IRB), used Tapestri as a basis to develop EPI-clone, which combines single-cell multi-omics with the readout of naturally occurring DNA methylation patterns as molecular barcodes for tracing clonality – the rapid proliferation of specific cells that precedes development of cancer. The method could be used to identify drug targets on pre-cancer clones that prevent disease progression, like methylation patterns as for epigenetic drugs like DNA methylation transferase inhibitors.
Lineage tracing holds the potential to explain how premalignant conditions like clonal hematopoiesis of indeterminate potential (CHIP) and myelodysplastic syndrome (MDS) can progress into hematologic cancers, and how cancerous subclones persist in relapse. Traditional methods for lineage tracing can be complex, low-throughput, or even harmful to normal cellular function. In the paper, titled "Clonal tracing with somatic epimutations reveals dynamics of blood aging," EPI-clone utilizes natural epigenetic patterns that are highly stable over long time scales.
Using Mission Bio's Tapestri Platform for high-throughput multi-omics measurement, researchers successfully captured hundreds of clonal differentiation trajectories across 230,358 single cells in both mouse and human hematopoiesis, with dual readout of epimutational barcodes and cell state information.
"EPI-clone provides insights into clonal selection during aging, potentially guiding the development of personalized, preventative treatments for diseases like cancers," said Velten. "The scale of our findings could only have been enabled by Tapestri, which allowed us simultaneous observation of single-cell genotype, phenotype, and clone."
"The impressive results of this study are a first step toward truly identifying, and therefore understanding, how certain clones contribute to cancer progression before they expand," said Adam Sciambi, Chief Technology Officer at Mission Bio. "We look forward to continued collaboration with the CRG team and others as we support the use of the Tapestri Platform's unique capabilities to make novel discoveries that change the course of disease understanding and treatment."
In aging mice, the researchers found that low output of old hematopoietic stem cells (HSCs) is restricted to a small number of expanded clones, while many functionally young clones persist in old age. In human aging, the team showed that clones associated with known clonal hematopoiesis (CH) mutations are part of a broader spectrum of age-related clonal expansions, with and without known driver mutations, displaying similar lineage biases. The results also showed that clonal complexity declines with age, leading to oligoclonal blood production.
To learn more about Tapestri and its ability to provide single-cell DNA + protein analysis at unmatched resolution, please visit missionbio.com/products/platform/.
About Mission Bio
Mission Bio is a leading life science company, specializing in the advancement of single-cell DNA and multiomics analysis. The company's Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies. Unlike traditional methods such as bulk sequencing, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies. Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments. Founded in 2014, Mission Bio has secured investment from firms including Mayfield Fund, Novo Growth, Cota Capital, and Agilent Technologies. With the Tapestri Platform, Mission Bio is setting the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies. To learn more about Mission Bio and the Tapestri Platform, please visit missionbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250520078702/en/
Contacts
Media Contact Consort Partners for Mission Biomissionbio@consortpartners.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
13 hours ago
- Wall Street Journal
A Startup Wants to Help Parents Rank Embryos for Longevity
Prospective parents using IVF will soon be able to rank embryos using genetic and other information in the hopes of extending the longevity of their offspring, according to the 25-year-old entrepreneur behind Nucleus Genomics, a DNA testing and analysis company. 'Lifespan has dramatically increased in the last 150 years,' said Kian Sadeghi, the company's founder and CEO. 'DNA testing to predict and reduce chronic disease can make it happen again.'
CBS News
a day ago
- CBS News
Body of 84-year-old man identified more than 31 years after being found floating near Florida bridge
Police in central Florida have identified the body of a man whose remains were first discovered over 31 years ago, using advanced DNA tests that led them to his relatives. Edman Eric Gleed had been listed as missing from Fairfax County, Virginia, by his son at the time of his death, the Clearwater Police Department said when they shared his identity Monday. He was 84. Previously, Gleed had been known to law enforcement as "Pinellas County John Doe 1993," since his body was found floating near a bridge in Clearwater, which is in Pinellas County outside of Tampa Bay, on Nov. 29, 1993. Clearwater police said Gleed's body was found without identification, and a folded pile of clothing near a lifeguard stand on the shore held no clues, either. The autopsy later conducted to determine a cause and manner of death was inconclusive, but the medical examiner did not suspect foul play, according to police. More than 31 years ago, the body of an unidentified man was found floating near the Clearwater Pass bridge. For all... Posted by Clearwater Police Department on Monday, June 2, 2025 Recently, samples of the then-unidentified man's DNA were collected again and submitted for testing to the nonprofit Moxxy Forensic Investigations, which analyzed them using investigative genetic genealogy. That technique aims to solve cold cases by matching an unknown person's DNA to their potential family members. The monthslong genealogical search uncovered connections to an 18th-century couple from Bristol, England, which allowed forensic investigators "to develop a candidate for the identity" of the man eventually confirmed to be Gleed, Clearwater police said. Gleed's identify was verified with a comparison sample from his son, who is now 94 and living in North Carolina. "We are happy that we are able to provide the family some answers and some closure as to what happened with their loved one," Clearwater's deputy police chief Michael Walek said in a statement. In a separate statement, Ed Adams, the assistant on Gleed's case at Moxxy Forensic Investigations, said the case "has been close to the hearts of everyone on the team." "We are all honored to have played a part in returning Edman Gleed to his family," Adams said.
New York Times
2 days ago
- New York Times
A DNA Technique is Finding Women Who Left Their Babies for Dead
One September evening in 2004, a Texas rancher noticed three buzzards circling near the road at the edge of his property. When he approached, he saw the body of an infant lying naked in the brush beside a barbed wire fence. Wayne Springer, then an investigator with the Medina County Sheriff's Department, was among the officers called to the scene. The infant was a newborn girl with the umbilical cord still attached. Deputy Springer knocked on doors up and down the road, looking for witnesses. He collected cheek swabs from dozens of people, hoping to find a DNA match. He tracked down carnival workers who had been in town for the Medina County Fair. On the anniversary of the baby's death, he staked out the cemetery in case someone stopped by her grave. Then, one day in 2023, his phone blew up. Former colleagues at the sheriff's department were calling to say that a 45-year-old woman, Maricela Frausto, had been identified as the baby's mother. Ms. Frausto, a mother of two who owned a restaurant in nearby Hondo, Texas, with her family, had been identified using a relatively new technique known as forensic genetic genealogy. Using DNA data from thousands of volunteer donors, investigators can create family trees and use them to match DNA found at crime scenes. Want all of The Times? Subscribe.
